5-Fluorouracil metabolite patterns in viable and necrotic tumor areas of murine colon carcinoma determined by 19F NMR spectroscopy by Kamm, Y.J.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23422
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
N O T E S
5-Fluorouracil Metabolite Patterns in Viable and 
Necrotic Tumor Areas of Murine Colon Carcinoma 
Determined by 19F NMR Spectroscopy
Wagener
M. C. M
High-resolution 19F NMR spectroscopy at 9.4 T was used to 
study the difference in the metabolite pattern of 5-fluorouracil 
(5-FU) between viable and necrotic tissues of C38 murine 
colon tumors grown in C57BI/6 mice. Studies were performed 
on perchloric acid extracts of these tumor fractions after 5-FU 
treatment. The 19F nuclear magnetic resonance spectra 
exhibited resonances representing 5-FU, the catabolites 
a-fluoro-|3-ureidopropionic acid and iv-fluoro-jB-alanine, as 
well as several fluoronucleotide anabolites. The absolute con­
centrations of anabolites and catabolites and the anabolite- 
to-catabolite ratio were significantly lower in the necrotic 
fraction than in the viable tumor fraction 50 min after admin­
istration of 5-FU, whereas the absolute concentration of 5-FU 
was the same. Therefore, in 5-FU metabolism studies with 
NMR spectroscopy, it is important to consider the necrotic 
contribution to the tumor volume.
Key words: 19F NMR spectroscopy; 5-fluorouracil; necrosis; 
metabolism. •
INTRODUCTION
5-Fluorouracil (5-FU) is still tho most important cyto­
static drug in tho treatment of colorectal cancer (1). To 
perform its cytostatic effect* it has to bo converted into 
active anabolites (2), Furthermore, 5-FU is degraded to 
inactive catabolites. Tim first conversion occurs predom­
inantly in tumor colls, tho second mostly in tho liver (3). 
Only a small percentage of tho 5-FlI is taken up in tumor 
cells and converted to tho therapeutically important 
anabolites: tho fluoronuelensidos (FNucs) and fluoro- 
nucleotides (FNucts). Tho functionally most important 
FNucts are 5-fluoro-2'-dnoxy uridine 5'-monophosphate 
(FdUMP) and 5-fluomundine 5'-triphosphate, the latter 
generally occurring at a much hi glim concentration (4), A
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large fraction of the administered 5-FU is degraded to 
catabolites of which 5,6-dihydro-5-fluorouracil (DHFU), 
a-fluoro-/3-ureidopropionic acid (FUPA), and a-fluoro-/3- 
alanine (FBAL) are the most important. Although it is 
generally agreed upon that the FNucts formed as a result 
of anabolism are responsible for the therapeutic effect of 
5-FU, the precise mechanism underlying the antitumor 
activity of the FNucts is still a matter of debate (1, 2).
To understand the effectiveness of 5-FU, its metabo­
lism has been studied in several tumor models and in 
patients, l9F NMR spectroscopy is one of the methods to 
monitor the presence of 5-FU and a number of its anabo­
lites and catabolites in tumor tissue (4). We have recently 
used this method to demonstrate the effect of various 
biomodulators on 5-FU metabolism in murine colon car­
cinomas (5). In vivo NMR studies have actually corre­
lated FNuct levels with therapeutic response (6-8). Com­
monly, in these studies, whole tumors are investigated 
and the amount of necrosis is neglected, although tumors 
may contain various quantities of necrosis that could 
affect the results.
The objective of the present study was to investigate to 
what extent the amount of necrosis affects mF NMR 
spectral profiles. The level of 5-FU and its metabolites 
may be different in the necrotic part, compared with the 
viable part of the tumor. To address this problem, viable 
and necrotic parts of a murine colon tumor were sepa­
rated after administration of 5-FU and NMR spectra 
of extracts of this material were measured.
MATERIALS AND METHODS
Tumor Model
Female C57BL/6 mice of 8 to 12 weeks of age were 
obtained from the Central Animal Laboratory of our uni­
versity. The C38 murine colon tumor, which is known to 
be sensitive to 5-FU, was acquired from Dr. P. Lelieveld 
of the REPGO-TNO Institute (Rijswijk, The Netherlands) 
and is described elsewhere [9], Tumor tissue fragments 
with a diameter of 3 mm were implanted subcutaneously 
in the right flank of the mouse. To investigate the influ­
ence of tumor size and thereby amount of necrosis, three 
groups of tumors of different weight were measured. In 
the first group (n = 6], the experiment was performed 
after 20 days, when the tumors reached a weight of 1.9 
(mean) ± 0.2 g (SE) necrosis included; in the second 
group (i7 = 8) after 27 days, with a total tumor weight of
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4.6 ± 0.6 g; and in the third group {n — 2) after 34 days, 
with a total tumor weight of 7.0 ± 0.05 g. No functional 
compromise of the mouse by the tumor burden was ob­
served. In addition, to get insight in the pharmacokinet­
ics of 5-FU, a time curve with respect to time after 5-FU 
administration was determined for 5-FU, anabolites and 
catabolites for the first weight group with the smallest 
tumors. The tumor was considered to be an ellipsoid, and 
its volume was estimated from three orthogonal diameter 
measurements (tumor volume in cubic millimeters = 
X X  Y X  Z X 0.5) (9). For the time curve, mice were 
divided into groups based on estimated tumor volume, 
and stratified randomization was conducted over the dif­
ferent time groups.
Chemotherapy
At the time of the experiment, the tumor-bearing mice 
received 5-FU at a dose of 115 mg/kg as bolus ip within
5 s. 5-FU was purchased from Roche (Mijdrecht, The 
Netherlands). The dose of 5-FU used (i.e., 115 mg/kg) is 
below the maximal tolerable dose (150 mg/kg) (10) and 
corresponds to 350 mg/m2 in man (11), which lies in the 
therapeutic range (370-500 mg/m2 for 5 days) (12).
Animals were killed by cervical dislocation 50 min 
after administration of 5-FU, except for the time curve 
study, because the various concentrations were mea­
sured at different time points. This time point was cho­
sen because of active and considerable metabolite forma­
tion, as followed from a time curve of whole tumors in 
our previous study (5). The tumor was excised within 2 
min and cleaved on ice to separate the necrotic tissue 
from the viable tumor tissue. Viable tumor and necrotic 
tissues were immediately frozen in liquid nitrogen until 
further processed by perchloric acid (PCA) extraction.
PCA Extraction
The frozen tissue was pulverized in a liquid nitrogen- 
chilled stainless steel mortar and ground to a fine pow­
der. Per gram of pulverized tissue, 5 ml of cold 0,9 M of 
PCA was added, and the sample was stirred with a glass 
rod and thoroughly mixed (1,500 rpm, 20 strokes). After 
homogenization, the sample was incubated for at least
1 h in a cold chamber on a shaker. The sample was 
centrifuged, the pellet was discarded, and the superna­
tant was neutralized with KOH and 4% (v/v) of a potas­
sium phosphate buffer (pH 6,5, 1 M, final concentration 
40 mM) before freeze-drying. After freeze-drying, the 
lyophilisate was dissolved in 0.8 ml of demineralized 
water, the pH of the sample was adjusted to 6.5, and the 
sample was freeze-dried again.
19F NMR Spectroscopy
19F NMR spectra were measured on a Bruker AMX 400 
using a dedicated 19F probe. Freeze-dried sample resi­
dues were dissolved in 0.4 ml of deminoralized water 
and placed in a 5-mm NMR tube, together with a coaxial 
insert containing 2H20  as lock substance, as well as 
parafluorobenzoic acid as an internal standard. Between 
3,000 and 30,000 transients were accumulated, depend­
ing on the signal-to-noise ratio required and the concen­
tration of the fluorine-containing compounds in the sam­
ple, Data acquisition parameters were: sweep width, 60 
kHz; flip angle, —45° with a pulse width of 6 /¿s; repeti­
tion time, 1.5 s; and temperature 298°K. No lH decou­
pling was used.
Analysis of 19F NMR Spectra
The 1<JF NMR resonance frequency of 5-FU was set to a 
chemical shift value of 0 ppm. The integrals of the signals 
of 5-FU (F), the FU anabolites (A) (FNucts plus any 
FNucs together), and the FU catabolites (C) (FUPA and 
FBAL) were calculated by comparison of the integrals of 
their signals to the integral of the H)F NMR resonance of 
the internal standard parafluorobenzoic acid (59,02 
ppm). Under the current conditions, no important satu­
ration of the resonances of A, C, and F was observed. This 
is concluded from an experiment in which the repetition 
time was set to 9 s instead of 1.5 s, but in which all other 
parameters were left unchanged. Relative comparison of 
the two spectra showed that the highest increase in signal 
intensity was observed for the internal standard when 
the repetition time was changed from 1,5 to 9 s. The 
internal standard was calibrated by adding a known con­
centration of 5-FU to an untreated tumor extract holding 
the reference capillary. The detection threshold of fluor- 
inated compounds is estimated to be —3 ¡xM in the ex­
tract solution. Peak areas were obtained by fitting a 
Lorentzian model function using NMRl software (New 
Methods Research, Inc., Syracuse, NY).
Statistics
For each group, mean values of concentrations have been 
presented with their standard error of the mean (SE). 
Differences in mean values between viable and necrotic 
tumor fractions were analyzed by the paired f-test (two- 
sided, a = 0.05) after log transformation (13),
RESULTS
19F NMR Detection of 5-FU Metabolite Patterns in Viable 
and Necrotic Tumor Tissues
Figure la  presents the liJF NMR spectrum of the extract of 
viable tumor tissue of a mouse 50 min after 5-FU treat­
ment, In addition to the peak of 5-FU (Peak 2 at 0 ppm), 
anabolite and catabolite peaks are seen. Various FNuct 
peaks indicated with 1 are ohsex'ved between 3 and 5 
ppm. In most spectra, three, sometimes four, different 
peaks can be distinguished, namely at 4.57 ± 0.03, 4.31 
± 0.03, 3.77 ± 0.00, and 3.74 ± 0,06 (not visible in Fig. 
1) ppm (±mean deviation). More detailed identification 
of the various nucleotide peaks might be possible on the 
basis of comparison with literature data (14-16) and with 
our own identification of FdUMP (small right peak from 
Group 1) and of the nucleoside peaks 5-fluorouridine and 
5-fhioro-2'-deoxyuridine (upfield from Group 1; not vis­
ible in Fig. 1) (5). However, chemical shifts reported 
seem to vary from one publication to another, because of 
the variation in sample conditions. Specific identifica­
tion of the other anabolite peaks requires the synthesis of 
appropriate reference compounds. For anabolites, the
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FIG. 1. 19F spectra of PCA extracts 
of C38 murine colon tumor tissue 
grown for 20 days after transplan­
tation and excised 50 min after 
5-FU injection: (a) viable tumor tis­
sue and (b) necrosis. Tissue quan­
tity: (a) 2.0 g; (b) 0.85 g; number of 
scans, 4,000; measurement time, 
2 h; Peak 1, three FNuct resonanc­
es; Peak 2, 5-FU; Peak 3, FU-PA; 
Peak 4, FBAL.
PPM
area under the curve of the total FNuct peak at —4 ppm is 
taken, At -17.01 ± 0.11 and -18.61 ± 0.10 ppm, upheld 
from 5-FU, two catabolite peaks are seen; FUPA (Peak 3) 
and FBAL (Peak 4), respectively. Sometimes two other 
small catabolite peaks are visible at -33 ppm (DHFU) 
and at 49 ppm (F-cations), not shown in this spectrum. 
The main amount of catabolites, however, is composed of 
FUPA and FBAL, which in this study are referred to the 
catabolites.
Figure lb  presents the spectrum of the extract from the 
excised necrotic area belonging to the same tumor. The 
spectrum shows signals for the major compounds also 
observed in the spectrum of the viable tumor tissue ex­
tract. However, relative and absolute signal intensities 
are clearly different.
Parameters for Response to Treatment
Possible parameters that may reflect the effectiveness of 
5-FU treatment are the absolute concentration of anabo- 
lites (A) representing cytotoxicity (4), of catabolites (C) 
representing detoxification, of total fluorine-containing 
compounds (T) including A, C, and F (14), the ratio of 
anabolites to 5-FU (A/F) (6), of anabolites to catabolites
(A/C), and of anabolites to total fluorine-containing com­
pounds (A/T] (17), In the present study, these parameters 
were evaluated both in viable and. necrotic tumor tissue.
Table 1 summarizes the evaluation of all data at 50 m in 
after 5-FU injection. From the table, it follows that in 
viable tumor tissue the absolute concentration of A is 
significantly higher than in the necrotic area. For the 
three weight groups together, these values are 88 ± 10, 
compared with 26 ± 5 nmol/g, P < 0.01. This is also the 
case for the absolute concentration of C (104 ± 8, com­
pared with 64 ± 8 nmol/g, P <  0.05), but not for the 
absolute concentration of F that seems similar in tumor 
and necrosis (75 ± 15, compared with 68 ± 11 nmol/g). 
The total concentration of fluorine-containing com­
pounds T is higher in the tumor fraction, compared with 
necrosis (266 ± 22, compared with 157 ± 18 nmol/g, P < 
0.01).
Because of the different relative changes between tu­
mor and necrosis of metabolite concentrations, some of 
the metabolite ratio’s are also different. Higher values are 
found in tumor tissue for the A/C ratio (0.91 ± 0.13, 
compared with 0,48 ± 0.09, P <  0.01) and the A/T ratio 
(0.32 ± 0.03, compared with 0.14 ± 0.02, P <  0.01). The
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Table 1
A /T
Tumor tissue ^  .  . n  i  a  1 —. :  _ . u i h
No. of Metabolite concentrations in nmol/gc tissue ±  SE
uay vveigi u animals A C F T -  A + C + F
Viable
Necrotic
20 1.3
0.5
±  0.2 
±  0.1
6 107 ± 14d 
23 ± 8
106 ± 16® 55 ± 18 
68 ± 9 64 ± 1 5
268 ± 32d 
155 ± 19
Viable
Necrotic
27 3.3
1.4
±  0.4 
±  0.3
8 81 ± 14d 
24 ± 8
100 ¿ 12 90 ± 24 
51 ± 10 70 ± 19
271 ±  38d 
145 ± 31
Ail tumors together1 
Viable
Necrotic
2.7
1.2
±  0.4 
±  0.2
16 88 ± 10d 
26 ± 5
104 ± 8e 75 ± 15 
64 ±  8 68 ± 11
266 ± 22d 
157 ±  18
Weight
Metabolite ratios ± SE
an CAT F/T A/C
Viable
Necrotic
1.3
0.5
0.40 ± 0.02e 
0.15 ± 0.05
0.41 ± 0.06 
0.46 ±  0.07
0.19 ± 0.05d 
0.39 ± 0.05
1.11 ± 0.22e 
0.43 ±0.17
Viable
Necrotic
3.3
1.4
0.28 ±  0.05 
0.14 ±  0.03
0.43 ± 0.08 
0.41 ± 0.10
0.28 ±  0.06 
0.46 ± 0.09
0.87 ± 0.19
0.54 ± 0.14
All tumors together 
Viable 
Necrotic
2.7
1.2
0.32 ± 0.03d 
0.14 ± 0.02
0.43 ± 0.05 
0.44 ± 0.05
0.25 ±  0.04d 
0.42 ± 0.05
0.91 ± 0.13d 
0.48 ± 0.09
a Days after tumor transplantation. 
b Weight of viable tumor tissue and necrosis separately,
c Quantities are given in nmol/g of extracted tissue. To achieve absolute amounts in nmoles, integrals have been multiplied by the conversion factor 104.8
(262 juM X 0.4 ml). 
d Significantly different, P <  0.01.
& Significantly different, P <  0.05.
f Including the third group (34 days, n =  2) not shown separately.
F/T ratio is even significantly lower in the tumor fraction 
(0.25 ± 0.04, compared with 0.42 ± 0.05, P < 0.01). The 
same tendency is seen in the separate weight groups.
Histological Determination of Percentage Viable Tumor 
Cells in Tumor and Necrotic Fractions
Although viable tumor and necrosis clearly can be di­
vided macroscopically, it is obvious that a perfect sepa­
ration of pure tumor and necrotic material is not possi­
ble. Histological examination of the tumors of the first 
group (plus two extra) and two tumors of the second 
group was performed; it was revealed that ~70% (first 
group) of the tumor fraction consisted of viable tumor cells 
and 30% of the necrotic fraction. For the two tumors of the 
second group, these percentages were in the same range.
Time Dependence of 5-FU Metabolite Pattern In Tumor 
and Necrotic Tissue
To determine the time course of 5-FU metabolism in 
viable and necrotic tumor tissues, 20 days after trans­
plantation, when the tumors had reached a mean total 
weight of 1.8 g, tumor extracts from both parts obtained 
at various time intervals after 5-FU administration were 
analyzed by 19F NMR. The results of these experiments 
are presented in  Fig. 2. Figure 2 (a-d) shows the absolute 
concentrations of A, G, Fr and T as observed at the vari­
ous time intervals. The results demonstrate that F in­
creases rapidly within the first 15 min, especially in the 
viable tumor part, to decrease thereafter. A and C in­
crease in a similar parallel way up from 0 (time of 5-FU 
injection) to —70 min. After an initial increase and a 
smaller decline thereafter, T stays at a stable level for the 
first 2 h. The tendencies are the same for the viable and 
necrotic tumor part. In the latter, the absolute values, 
except the concentration of F, are lower most of the time. 
This is particularly the case for the period after 50 min.
DISCUSSION
Only a few liJF NMR extract studies of 5-FU-treated tu­
mors have been reported (4-6, 18, 19). Most of the 19F 
NMR studies on 5-FU metabolism in animals or man 
have been conducted in vivo. In addition, H)F NMR anal­
ysis has been performed in cell cultures (20). The role of 
necrosis in the interpretation of results of 5-FU metabo­
lism has not been studied yet by 19F NMR. Because 5-FU 
metabolite levels may be quite different in necrotic parts, 
compared with viable parts of a tumor, the necrotic frac­
tion may contribute significantly to the li]F NMR spectral 
profile of a tumor. This is of importance not only for in 
vitro studies, but especially for in vivo studies. In this 
study, we have attempted to characterize a possible dif­
ference in 5-FU metabolite levels between necrotic and 
tumor fractions of a murine colon carcinoma.
In the necrotic fraction of the tumor, the absolute con­
centrations of all metabolites were lower than in the 
viable tumor fraction. The initial higher increase of 5-FU 
in viable tumor parts, compared with necrotic parts, most 
likely is caused by better vascularization of viable tumor
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FIG. 2. (a-d) Concentration anabolites (A), catabolites (C), 5-FU (F), and total fluorine-containing compounds (T) in nmol/g of tissue in 
extracts of C38 murine colon tumor (mean total tumor weight 1.8 g) excised 0 (<30 s) to 120 min after 5-FU injection (n = 6, mean ± SE). 
A, viable tumor tissue; • ,  necrotic tissue.
tissue, After ~30 min, however, 5-FU levels become sim­
ilar in both parts. Various processes may contribute to 
this behavior. Diffusion of 5-FU into necrotic tissue will 
occur, but at the same time 5-FU is better cleared from 
the well-vascularized, viable part of the tumor. Another 
process may be acidification of the viable cells in the 
necrotic part, inducing local retention of 5-FU (21). 
Whatever the responsible mechanism may be, the results 
indicate that 5-FU permeates into the necrotic area to a 
similar level as in the viable tumor area.
Anabolite levels are higher in tumor parts than in 
necrotic parts, which could be expected on the basis of 
the metabolic activity in viable tumor cells. Diffusion 
processes apparently are not able to equalize anabolite 
levels among viable and necrotic tumor parts. Consider­
ing the amount of viable tumor cells still present in the 
necrotic fraction, it is conceivable that an appreciable 
part of the anabolites in this fraction arise from these 
cells. In this tumor model, the amount of necrosis seems 
not of major importance for the response to therapy, 
because 5-FU reaches also the necrotic fraction wherein 
the viable cells anabolites can be formed.
Because catabolites are produced predominantly by 
detoxification of 5-FU in the liver, the well-vascularized
part of the tumor will be supplied by increasing amounts 
of these catabolites, as is observed in this study. The 
lower levels of catabolites in the necrotic part of the 
tumor are likely caused by bad vascularization, which is 
not sufficiently compensated by diffusion from viable 
tumor parts.
It is common practice in animal studies to take tumors 
not exceeding 10% of body weight. This because of the 
possible occurrence of anemia influencing tumor perfu­
sion (viscosity] and oxygenation, and functional compro­
mise by the tumor burden (22). As a result, substantial 
necrosis may develop. From this study, it follows that, in 
a tumor with a significant amount of necrosis, the con­
version from 5-FU to anabolites and catabolites may be 
underestimated, as well as the A/C ratio. Therefore, it is 
of importance in 5-FU metabolism studies either to lim it 
the amount of necrosis or to consider a possible contri­
bution of necrosis.
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